Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06336889 · ClinicalTrials.gov registry record
Pelvic Angioembolization: A Prospective Multi-Institutional Study (Data From All Campuses Will be Used)
A clinical trial of Pelvic Hemorrhage, sponsored by Methodist Health System.
- Recruiting
- Registry status
- 400
- Enrollment target
- 1
- Study location
NCT06336889: Recruiting study of Pelvic Hemorrhage, sponsored by Methodist Health System.
NCT06336889 is a study of Pelvic Hemorrhage that is actively recruiting participants, run by Methodist Health System. The registered enrollment target is 400 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06336889, a study of Pelvic Hemorrhage, is actively recruiting participants, sponsored by Methodist Health System.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigator's propose a multicenter prospective observational study to investigate the use of embolization in patients with negative angiogram and to ascertain the optimal level of treatment when the angiogram is positive; non-selective vs. selective embolization.
Conditions Studied
Interventions
- PROCEDURE Pelvic Angioembolization
Study Locations (1)
Texas
- Methodist Dallas Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2017-10-26 |
| Est. Completion | 2024-10 |
What NCT06336889 shows while recruiting
NCT06336889 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Pelvic Hemorrhage appearing as the primary indexed condition, and to 1 intervention - of which Pelvic Angioembolization is the first listed.
NCT06336889 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06336889 about?
NCT06336889 is a clinical study titled "Pelvic Angioembolization: A Prospective Multi-Institutional Study (Data From All Campuses Will be Used)". The investigator's propose a multicenter prospective observational study to investigate the use of embolization in patients with negative angiogram and to ascertain the optimal level of treatment when the angiogram is positive; non-selective vs. selective embolization.
What is the current status of trial NCT06336889?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2017-10-26. Estimated completion is 2024-10.
What conditions does trial NCT06336889 study?
This clinical trial studies the following conditions: Pelvic Hemorrhage.
What interventions are being tested in trial NCT06336889?
The interventions under investigation include: Pelvic Angioembolization (PROCEDURE).
Who is sponsoring clinical trial NCT06336889?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06336889 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI